Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

Blood (2015) 126 (23): 27.

https://doi.org/10.1182/blood.V126.23.27.27

Published: 2015

Journal Articles

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

Blood (2012) 120 (24): 4706–4711.

https://doi.org/10.1182/blood-2012-04-420596

Published: 2012

Includes: Supplemental data

Journal Articles

IMWG consensus on maintenance therapy in multiple myeloma

Blood (2012) 119 (13): 3003–3015.

https://doi.org/10.1182/blood-2011-11-374249

Published: 2012

Journal Articles

A Family with Hereditary Elliptocytosis: Variable Clinical Severity Caused by Three Mutations in the α-Spectrin Gene,

Paul Hubert Frans Franck, PhD, Cobie Postma, Marjan Veuger, PhD, Pierre Wijermans, MD, Frans A Kuypers, PhD

Blood (2011) 118 (21): 3167.

https://doi.org/10.1182/blood.V118.21.3167.3167

Published: 2011

Journal Articles

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Blood (2011) 118 (5): 1239–1247.

https://doi.org/10.1182/blood-2011-03-341669

Published: 2011

Journal Articles

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

Blood (2011) 117 (11): 3025–3031.

https://doi.org/10.1182/blood-2010-09-307645

Published: 2011

Journal Articles

Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial

Michael Lubbert, Claudia Schmoor, Björn Rüter, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Rainer Claus, Barbara Deschler, Björn W. Hackanson, Konstanze Döhner, Pierre Wijermans, Hartmut Döhner

Blood (2010) 116 (21): 2185.

https://doi.org/10.1182/blood.V116.21.2185.2185

Published: 2010

Journal Articles

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Blood (2010) 116 (21): 40.

https://doi.org/10.1182/blood.V116.21.40.40

Published: 2010

Journal Articles

Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma

Blood (2010) 116 (21): 2396.

https://doi.org/10.1182/blood.V116.21.2396.2396

Published: 2010

Journal Articles

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Blood (2010) 115 (6): 1113–1120.

https://doi.org/10.1182/blood-2009-05-222539

Published: 2010

Journal Articles

Successful Harvesting of Peripheral Hematopoietic Stem Cells after Induction Treatment with Bortezomib, Adriamycin, Dexamethasone (PAD) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Blood (2008) 112 (11): 3470.

https://doi.org/10.1182/blood.V112.11.3470.3470

Published: 2008

Journal Articles

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups

Pierre WijerMans, Stefan Suciu, Liliana Baila, Uwe Platzbecker, Aristoteles Giagounidis, Dominik Selleslag, Boris Labar, Helmut Salih, Filip Beeldens, Petra Muus, Theo de Witte, Michael Lübbert, MD, PhD

Blood (2008) 112 (11): 226.

https://doi.org/10.1182/blood.V112.11.226.226

Published: 2008

Journal Articles

Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7

Björn Rüter, Pierre Wijermans, Rainer Claus, Regina Kunzmann, Michael Lübbert

Blood (2007) 110 (3): 1080–1082.

https://doi.org/10.1182/blood-2007-03-080630

Published: 2007

Journal Articles

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Jan J. Cornelissen, Wim L. J. van Putten, Leo F. Verdonck, Matthias Theobald, Emanuel Jacky, Simon M. G. Daenen, Marinus van Marwijk Kooy, Pierre Wijermans, Harry Schouten, Peter C. Huijgens, Hans van der Lelie, Martin Fey, Augustin Ferrant, Johan Maertens, Alois Gratwohl, Bob Lowenberg

Blood (2007) 109 (9): 3658–3666.

https://doi.org/10.1182/blood-2006-06-025627

Published: 2007

Includes: Supplemental data

Journal Articles

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Pieter Sonneveld, MD, Wim van Putten, MSc, Harald Holte, MD, Douwe Biesma, MD, Marinus van Marwijk-Kooy, MD, Mark Kramer, MD, Pierre Wijermans, MD, Monique Steijaert, Peter Huijgens, MD, Mikael Eriksson, MD

Blood (2005) 106 (11): 16.

https://doi.org/10.1182/blood.V106.11.16.16

Published: 2005

Journal Articles

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment

Michael Daskalakis, Tudung T. Nguyen, Carvell Nguyen, Per Guldberg, Gabriele Köhler, Pierre Wijermans, Peter A. Jones, Michael Lübbert

Blood (2002) 100 (8): 2957–2964.

https://doi.org/10.1182/blood.V100.8.2957

Published: 2002

Journal Articles

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS

Theo de Witte, Stefan Suciu, Gregor Verhoef, Boris Labar, Eric Archimbaud, Carlo Aul, Dominique Selleslag, Augustin Ferrant, Pierre Wijermans, Franco Mandelli, Sergio Amadori, Ulrich Jehn, Petra Muus, Marc Boogaerts, Robert Zittoun, Alois Gratwohl, Heintz Zwierzina, Anne Hagemeijer, Roel Willemze

Blood (2001) 98 (8): 2326–2331.

https://doi.org/10.1182/blood.V98.8.2326

Published: 2001

NARROW

Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

IMWG consensus on maintenance therapy in multiple myeloma

A Family with Hereditary Elliptocytosis: Variable Clinical Severity Caused by Three Mutations in the α-Spectrin Gene,

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Successful Harvesting of Peripheral Hematopoietic Stem Cells after Induction Treatment with Bortezomib, Adriamycin, Dexamethasone (PAD) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups

Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only